FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer

Elise C Hoover; Olivia M Ruggiero; Rachel N Swingler; Emily S Day

doi:10.1021/acsomega.3c10275

FZD7-Targeted Nanoparticles to Enhance Doxorubicin Treatment of Triple-Negative Breast Cancer

ACS Omega. 2024 Mar 16;9(12):14323-14335. doi: 10.1021/acsomega.3c10275. eCollection 2024 Mar 26.

Authors

Elise C Hoover¹, Olivia M Ruggiero¹, Rachel N Swingler¹, Emily S Day^{1

2

3}

Affiliations

¹ Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.
² Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, United States.
³ Helen F. Graham Cancer Center and Research Institute, Newark, Delaware 19713, United States.

Abstract

Doxorubicin (DOX) is a chemotherapy agent commonly used to treat triple-negative breast cancer (TNBC), but it has insufficient efficacy against the disease and considerable toxicity due to its off-target delivery. To improve the specificity of DOX for TNBC, we encapsulated it in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) coated with antibodies against Frizzled7 (FZD7), a receptor that is overexpressed on TNBC cells and which is a key activator of the Wnt signaling pathway. In vitro studies show that DOX encapsulation does not hinder its ability to localize to the nucleus in human TNBC cell cultures and that DOX delivered via NPs induces apoptosis and DNA damage via H2A.X phosphorylation to the same degree as freely delivered DOX. FZD7-targeted NPs delivering DOX caused significantly greater inhibition of metabolic activity and led to a smaller cell population following treatment when compared to freely delivered DOX or DOX-loaded NPs coated only with poly(ethylene glycol) (PEG). The FZD7 antibodies additionally provided significant levels of Wnt pathway inhibition, as demonstrated by an increase in β-catenin phosphorylation, indicative of β-catenin destruction and downregulation. These results show that FZD7-targeted platforms have great promise for improving the therapeutic window of otherwise toxic chemotherapies like DOX in TNBC and other cancers that display the overexpression of FZD7 receptors.